Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia

References

• Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10:37-50; PMID:19956173; https://doi.org/10.1038/nrc2764
   PubMed Web of Science ®Google Scholar
• Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, Escaramis G, Jares P, Beà S, González-Díaz M, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011; 475(7354):101-5; PMID:21642962; https://doi.org/10.1038/nature10113
   PubMed Web of Science ®Google Scholar
• Gonzalez-Rodriguez AP, Contesti J, Huergo-Zapico L, López-Soto A, Fernández-Guizán A, Acebes-Huerta A, Gonzalez-Huerta AJ, Gonzalez E, Fernandez-Alvarez C, Gonzalez S. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. Leuk Lymphoma 2010; 51:1829-36; PMID:20846097; https://doi.org/10.3109/10428194.2010.503820
   PubMed Web of Science ®Google Scholar
• Palmer S, Hanson CA, Zent CS, Porrata LF, LaPlant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Diane F, et al. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008; 141:607-14; PMID:18384436; https://doi.org/10.1111/j.1365-2141.2008.07070.x
   PubMed Web of Science ®Google Scholar
• Huergo-Zapico L, Acebes-Huerta A, Gonzalez-Rodriguez AP, Contesti J, Gonzalez-García E, Payer AR, Villa-Álvarez M, Fernández-Guizán A, López-Soto A, Gonzalez S. Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease. PLoS One 2014; 9:e108326; PMID:25286418; https://doi.org/10.1371/journal.pone.0108326
   PubMed Web of Science ®Google Scholar
• Riches JC, Gribben JG. Understanding the immunodeficiency in chronic lymphocytic leukemia: Potential clinical implications. Hematol Oncol Clin North Am 2013; 27:207-35; PMID:23561470; https://doi.org/10.1016/j.hoc.2013.01.003
   PubMed Web of Science ®Google Scholar
• Moreira J, Rabe KG, Cerhan JR, Kay NE, Wilson JW, Call TG, Leis JF, Jelinek DF, Schwager SM, Bowen DA, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): A cohort study of newly diagnosed cases compared to controls. Leukemia 2013; 27:136-41; PMID:22781591; https://doi.org/10.1038/leu.2012.187
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118:2427-37; PMID:18551193; https://doi.org/10.1172/JCI35017
   PubMed Web of Science ®Google Scholar
• Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull 2008; 87:49-62; PMID:18755702; https://doi.org/10.1093/bmb/ldn034
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 2015; 27:450-61; PMID:25858804; https://doi.org/10.1016/j.ccell.2015.03.001
   PubMed Web of Science ®Google Scholar
• Weber J. Immune checkpoint proteins: A new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010; 37:430-9; PMID:21074057; https://doi.org/10.1053/j.seminoncol.2010.09.005
   PubMed Web of Science ®Google Scholar
• Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997; 7:273-82; PMID:9285411; https://doi.org/10.1016/S1074-7613(00)80529-4
   PubMed Web of Science ®Google Scholar
• Colonna M, Navarro F, Bellón T, Llano M, García P, Samaridis J, Angman L, Cella M, López-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186:1809-18; PMID:9382880; https://doi.org/10.1084/jem.186.11.1809
   PubMed Web of Science ®Google Scholar
• Lamar DL, Weyand CM, Goronzy JJ. Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages. Blood 2010; 115:3278-86; PMID:20194892; https://doi.org/10.1182/blood-2009-09-243493
   PubMed Web of Science ®Google Scholar
• Liang S, Zhang W, Horuzsko A. Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. Eur J Immunol 2006; 36:2457-71; PMID:16897816; https://doi.org/10.1002/eji.200636031
   PubMed Web of Science ®Google Scholar
• Navarro F, Llano M, Bellón T, Colonna M, Geraghty DE, López-Botet M. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999; 29:277-83; PMID:9933109; https://doi.org/10.1002/(SICI)1521-4141(199901)29:01<277::AID-IMMU277>3.0.CO;2-4
   PubMed Web of Science ®Google Scholar
• Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B, et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci U S A 2003; 100:8856-61; PMID:12853576; https://doi.org/10.1073/pnas.1431057100
   PubMed Web of Science ®Google Scholar
• Bellon T, Kitzig F, Sayos J, Lopez-Botet M. Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor. J Immunol 2002; 168:3351-9; PMID:11907092; https://doi.org/10.4049/jimmunol.168.7.3351
   PubMed Web of Science ®Google Scholar
• Naji A, Menier C, Morandi F, Agaugué S, Maki G, Ferretti E, Bruel S, Pistoia V, Carosella ED, Rouas-Freiss N. Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses. J Immunol 2014; 192:1536-46; PMID:24453251; https://doi.org/10.4049/jimmunol.1300438
   PubMed Web of Science ®Google Scholar
• Saverino D, Fabbi M, Ghiotto F, Merlo A, Bruno S, Zarcone D, Tenca C, Tiso M, Santoro G, Anastasi G, et al. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. J Immunol 2000; 165:3742-55; PMID:11034379; https://doi.org/10.4049/jimmunol.165.7.3742
   PubMed Web of Science ®Google Scholar
• Cosman D, Fanger N, Borges L. Human cytomegalovirus, MHC class I and inhibitory signalling receptors: more questions than answers. Immunol Rev 1999; 168:177-85; PMID:10399074; https://doi.org/10.1111/j.1600-065X.1999.tb01292.x
   PubMed Web of Science ®Google Scholar
• Naji A, Menier C, Maki G, Carosella ED, Rouas-Freiss N. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction. Leukemia 2012; 26:1889-92; PMID:22441169; https://doi.org/10.1038/leu.2012.62
   PubMed Web of Science ®Google Scholar
• Dietrich J, Cella M, Colonna M. Ig-like transcript 2 (ILT2)/leukocyte Ig-like receptor 1 (LIR1) inhibits TCR signaling and actin cytoskeleton reorganization. J Immunol 2001; 166:2514-21; PMID:11160312; https://doi.org/10.4049/jimmunol.166.4.2514
   PubMed Web of Science ®Google Scholar
• Lin A, Chen HX, Zhu CC, Zhang X, Xu HH, Zhang JG, Wang Q, Zhou WJ, Yan WH. Aberrant human leukocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med 2010; 14:2162-71; PMID:19799650; https://doi.org/10.1111/j.1582-4934.2009.00917.x
   PubMed Web of Science ®Google Scholar
• Attia MA, Nosair NA, Gawally A, Elnagar G, Elshafey EM. HLA-G expression as a prognostic indicator in B-cell chronic lymphocytic leukemia. Acta Haematol 2014; 132:53-8; PMID:24557341; https://doi.org/10.1159/000353757
   PubMed Web of Science ®Google Scholar
• Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005; 105:1694-8; PMID:15466928; https://doi.org/10.1182/blood-2004-08-3335
   PubMed Web of Science ®Google Scholar
• Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: Implication of HLA-G. Leukemia 2008; 22:998-1006; PMID:18288133; https://doi.org/10.1038/leu.2008.15
   PubMed Web of Science ®Google Scholar
• Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant 2010; 16:612-21; PMID:20139023; https://doi.org/10.1016/j.bbmt.2010.01.019
   PubMed Web of Science ®Google Scholar
• Rouas-Freiss N, Moreau P, LeMaoult J, Carosella ED. The dual role of HLA-G in cancer. J Immunol Res 2014; 2014:359748; PMID:24800261; https://doi.org/10.1155/2014/359748
   PubMed Web of Science ®Google Scholar
• Ince MN, Harnisch B, Xu Z, Lee SK, Lange C, Moretta L, Lederman M, Lieberman J. Increased expression of the natural killer cell inhibitory receptor CD85j/ILT2 on antigen-specific effector CD8 T cells and its impact on CD8 T-cell function. Immunology 2004; 112:531-42; PMID:15270723; https://doi.org/10.1046/j.1365-2567.2004.01907.x
   PubMed Web of Science ®Google Scholar
• Greipp PT, Smoley SA, Viswanatha DS, Frederick LS, Rabe KG, Sharma RG, Slager SL, Van Dyke DL, Shanafelt TD, Tschumper RC, et al. Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. Br J Haematol 2013; 163:326-33; PMID:24032430; https://doi.org/10.1111/bjh.12534
   PubMed Web of Science ®Google Scholar
• Guièze R, Robbe P, Clifford R, de Guibert S, Pereira B, Timbs A, Dilhuydy MS, Cabes M, Ysebaert L, Burns A, et al. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood 2015; 126:2110-7; PMID:26316624; https://doi.org/10.1182/blood-2015-05-647578
   PubMed Web of Science ®Google Scholar
• Knittel G, Liedgens P, Reinhardt HC. Targeting ATM-deficient CLL through interference with DNA repair pathways. Front Genet 2015; 6:207; PMID:26113859; https://doi.org/10.3389/fgene.2015.00207
   PubMed Web of Science ®Google Scholar
• Chiorazzi N. Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012:76-87; PMID:23233564; https://doi.org/10.1182/asheducation-2012.1.76
   PubMed Web of Science ®Google Scholar
• Sancho D, Gomez M, Sanchez-Madrid F. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol 2005; 26:136-40; PMID:15745855; https://doi.org/10.1016/j.it.2004.12.006
   PubMed Web of Science ®Google Scholar
• Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013; 121:1612-21; PMID:23247726; https://doi.org/10.1182/blood-2012-09-457531
   PubMed Web of Science ®Google Scholar
• Acebes-Huerta A, Huergo-Zapico L, Gonzalez-Rodriguez AP, Fernandez-Guizan A, Payer AR, López-Soto A, Gonzalez S. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int 2014; 2014:265840; PMID:25313353; https://doi.org/10.1155/2014/265840
   PubMed Web of Science ®Google Scholar
• Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK. Interferon gamma inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med 1993; 177:213-8; PMID:7678114; https://doi.org/10.1084/jem.177.1.213
   PubMed Web of Science ®Google Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood 2015; 126:573-81; PMID:26084672; https://doi.org/10.1182/blood-2015-03-567388
   PubMed Web of Science ®Google Scholar
• Favier B, Lemaoult J, Lesport E, Carosella ED. ILT2/HLA-G interaction impairs NK-cell functions through the inhibition of the late but not the early events of the NK-cell activating synapse. FASEB J 2010; 24:689-99; PMID:19841038; https://doi.org/10.1096/fj.09-135194
   PubMed Web of Science ®Google Scholar
• Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D'Arena G, Coscia M, Laurenti L, et al. HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: Impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica 2014; 99:888-96; PMID:24362551; https://doi.org/10.3324/haematol.2013.095281
   PubMed Web of Science ®Google Scholar
• Ozet G, Falay M, Dagdas S, Ceran F. Determination of HLA-G Expression and evaluation of its role as a prognostic factor in chronic lymphocytic leukemia. J Clin Lab Anal 2016; 30(5):399-403; PMID:26303056
   PubMed Web of Science ®Google Scholar
• Erikci AA, Karagoz B, Ozyurt M, Ozturk A, Kilic S, Bilgi O. HLA-G expression in B chronic lymphocytic leukemia: A new prognostic marker? Hematology 2009; 14:101-5; PMID:19298722; https://doi.org/10.1179/102453309X385197
   PubMed Web of Science ®Google Scholar
• Perez-Chacon G, Rosado S, Rebolleda N, Losada-Fernandez I, Vargas JA, Morado M, Jorda J, Perez-Aciego P. Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. Int J Lab Hematol 2009; 31:327-37; PMID:18241213; https://doi.org/10.1111/j.1751-553X.2008.01030.x
   PubMed Web of Science ®Google Scholar
• Stankovic T, Skowronska A. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. Leuk Lymphoma 2014; 55:1227-39; PMID:23906020; https://doi.org/10.3109/10428194.2013.829919
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-6; PMID:11136261; https://doi.org/10.1056/NEJM200012283432602
   PubMed Web of Science ®Google Scholar
• Marasca R, Maffei R, Martinelli S, Fiorcari S, Bulgarelli J, Debbia G, Rossi D, Rossi FM, Rigolin GM, Martinelli S, et al. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: Prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematol Oncol 2013; 31:88-95; PMID:23027683; https://doi.org/10.1002/hon.2028
   PubMed Web of Science ®Google Scholar
• Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Dürig J, Küppers R. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J. Exp. Med 2012; 209(12):2183-98; PMID:23091163; https://doi.org/10.1084/jem.20120833
   PubMed Web of Science ®Google Scholar
• Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013; 121(9):1612-21; PMID:23247726; https://doi.org/10.1182/blood-2012-09-457531
   PubMed Web of Science ®Google Scholar
• Riches JC, Gribben JG. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. Semin Hematol 2014; 51(3):228-34; PMID:25048786; https://doi.org/10.1053/j.seminhematol.2014.05.006
   PubMed Web of Science ®Google Scholar